Releases
19. June, 2025
Strengthening Executive Management with the promotion of Martin Juhl
On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of...
Releases
28. May, 2025
Positive top-line results from its final CT001 Study 0202
On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from...
Releases
28. February, 2025
Annual Report 2024
Today, Friday 28. February, Cessatech has released the Annual Report for 20024. We have...
Releases
4. February, 2025
Positive Notified Body opinion under MDR for CT001
On 4 February – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...
29. October, 2024
Company presentation Nordnet – follow up
In case you did not have time to watch the online Nordnet company presentation,...
Releases
16. October, 2024
Halfway milestone patient recruitment in Paediatric Study 0202
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with...
Releases
26. August, 2024
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...
Releases
12. August, 2024
Cessatech extends Loan Facility Agreement to DKK 10 million…
Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...
Releases
5. July, 2024
Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors
Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...
Releases
28. June, 2024
New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001
On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...
Releases
3. June, 2024
Cessatech announces superior simulated pain efficacy in children
Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...
Releases
27. May, 2024
Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001
Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing...